W.L. Gore Acquires Conformal Medical: Next-Gen LAAO Technology and the Battle for the $2B Left Atrial Appendage Closure Market

The Deal at a Glance

On January 7, 2026, W.L. Gore & Associates announced a definitive agreement to acquire Conformal Medical, Inc., a privately held medical device company developing next-generation left atrial appendage occlusion (LAAO) technology. The transaction closed on February 19, 2026 — just 45 days after announcement — reflecting a swift diligence and integration process.

Financial terms were not disclosed. For context, the deal is notable as a rare outright acquisition by privately held Gore, which historically has grown organically through its materials science innovation pipeline. The acquisition places Gore in direct competition with Boston Scientific and Abbott in one of the fastest-growing segments of structural heart intervention.

The LAAO Opportunity: Why This Market Matters

To understand why Gore would make a rare acquisition to enter this space, you need to understand the clinical problem and the market dynamics.

The Clinical Problem

Atrial fibrillation (AFib) affects approximately 60 million people worldwide. AFib causes the left atrium to quiver rather than contract effectively, which allows blood to pool in the left atrial appendage (LAA) — a small, ear-shaped pouch extending from the left atrium. This pooled blood can form clots, and if a clot escapes into the bloodstream, it can travel to the brain and cause a stroke.

People with AFib have a five times higher risk of stroke compared to the general population. Between 70% and 95% of AFib patients fall into the non-valvular category. Standard treatment is long-term oral anticoagulation therapy, but this approach has significant limitations:

• Non-adherence: Up to 40% of patients stop taking their anticoagulants, leaving them unprotected
• Bleeding risk: Anticoagulants carry a risk of serious bleeding events
• Contraindications: Many patients cannot tolerate anticoagulation due to other medical conditions

Left atrial appendage occlusion (LAAO) offers a one-time mechanical alternative: permanently sealing off the LAA to prevent clot formation, potentially eliminating the need for long-term anticoagulation.

Market Size and Growth

The LAAO device market was valued at approximately $1.87 billion in 2025 and is projected to reach $2.14 billion by 2026, according to Precedence Research, with some estimates projecting growth to $7.81 billion by 2035 at a CAGR of 13.8%. AFib is projected to reach more than 12 million cases in the US alone by 2030, according to the American Heart Association. Other estimates place the market as high as $2.2 billion currently, with high single-digit growth projected over the next five years.

The market is dominated by two players:

Other competitors include AtriCure (AtriClip for surgical/epicardial approach), Occlutech, Lifetech, and J&J (which acquired Laminar for ~$400 million to develop a rotational LAAO device). Boston Scientific reported Watchman sales of $506 million in Q1 2026, representing 19.2% year-over-year growth — though this was below expectations, contributing to the company lowering its 2026 guidance.

Conformal Medical's Technology: A Different Approach

Conformal Medical's CLAAS AcuForm system takes a fundamentally different technical approach from the market leaders.

How It Differs

Boston Scientific's WATCHMAN and Abbott's Amulet are both nitinol frame-based devices — metal cages that expand to fill the LAA. They come in multiple sizes, and the interventionalist must select the correct size based on the patient's LAA anatomy, which varies enormously in shape (chicken wing, windsock, cauliflower, cactus morphologies).

Conformal's CLAAS AcuForm features a nitinol endoskeleton with a proprietary foam matrix implant designed to conform to complex and variable anatomies. The device is designed in just two sizes (versus 5+ sizes for WATCHMAN and Amulet), and the key claimed advantages are:

1. Fewer sizes, broader coverage — The foam material compresses and expands to conform to the individual patient's LAA shape across a wider range of anatomies per size. This simplifies the procedure and reduces inventory requirements for hospitals.

2. Complete seal — The foam is designed to fill irregularly shaped appendages more completely than rigid metal frames, potentially achieving better sealing of the LAA and reducing peridevice leak rates.

3. Same-day procedure potential — Conformal Medical's technology is designed to transform LAAO into a same-day procedure, moving clinical practice away from general anesthesia and overnight hospitalizations.

The CONFORM Pivotal Trial

The CLAAS AcuForm system is being evaluated in the CONFORM Pivotal Trial, a 1,600-patient study. At the time of the acquisition announcement, the trial was approximately 30% enrolled. The trial is designed to evaluate the safety and effectiveness of the device compared to standard medical therapy in patients with non-valvular AFib.

The device has not received FDA clearance or CE marking. It is currently available only for clinical investigation. This means Gore is acquiring a technology in mid-stage clinical development, with significant regulatory milestones still ahead.

Why Gore Made This Acquisition

W.L. Gore is a unique company in the medical device landscape. Privately held and headquartered in Newark, Delaware, Gore is best known for its GORE-TEX fabric but has a substantial medical device business built on its expertise in advanced materials — particularly expanded polytetrafluoroethylene (ePTFE) and fluoropolymers. Gore's medical products include vascular grafts, endovascular stent grafts, and surgical meshes.

Strategic Rationale

Several factors make this acquisition logical for Gore:

1. Materials science synergy — Conformal's foam-based LAAO technology aligns with Gore's core competence in advanced materials engineering. Gore has decades of experience designing implantable materials that interact safely with human tissue.

2. Endovascular market expansion — Gore already has a strong presence in endovascular stent grafts (for aortic aneurysm repair) and vascular grafts. Adding LAAO technology extends its reach into structural heart interventions while leveraging existing sales channels targeting interventional cardiologists and electrophysiologists.

3. Platform strategy — Bret Snyder, Gore's board chair and CEO, stated that the acquisition "further strengthens Gore's product development pipeline in endovascular treatment, with the goal of reaching more patients." With approximately 13,000 associates and $5.3 billion in annual revenue, Gore has the scale to invest in the long clinical and regulatory pathway ahead for the CLAAS AcuForm system.

4. Rare strategic move signals conviction — Gore rarely makes acquisitions, preferring organic growth through its internal innovation culture. The decision to acquire Conformal — completed within just 45 days from announcement — signals strong conviction in both the technology and the market opportunity.

Competitive Dynamics: How This Reshapes the LAAO Market

Gore's entry adds a formidable competitor to the LAAO space. The competitive landscape in 2026 includes:

Incumbents

• Boston Scientific (WATCHMAN) — The dominant player with ~75% market share. The fourth-generation WATCHMAN device is expected to enter pivotal US trials in 2026, designed to better seal complex LAA anatomy. Boston Scientific is also pursuing expanded indications beyond patients who cannot tolerate long-term anticoagulation, potentially unlocking a market of 20 million AFib patients by 2030.

• Abbott (Amulet) — The clear #2 with ~20% share. Abbott's dual-seal design and strong clinical evidence base provide a differentiated positioning. The company is reportedly developing pulsed-field ablation-compatible occluders for dual-therapy platforms.

Emerging Competitors

What This Means for Market Dynamics

1. The market is moving beyond two players. With Gore, J&J, and potentially others entering, the LAAO market is transitioning from a near-duopoly to a more competitive landscape. This should drive innovation and potentially improve pricing dynamics for hospitals.

2. Technology differentiation matters. Conformal's foam-based approach is fundamentally different from nitinol frame devices. If the CONFORM trial demonstrates comparable or superior outcomes — particularly in reducing peridevice leak — it could establish a new category of conformable LAAO devices.

3. Procedure volume growth is the key driver. Boston Scientific expects the addressable patient population for LAAO to expand from its current indication (patients who cannot tolerate long-term anticoagulation) to potentially 20 million AFib patients by 2030. If the expanded indication is approved, all LAAO device manufacturers will benefit from a rapidly growing market.

Regulatory Pathway Forward

The CLAAS AcuForm system's path to market involves several regulatory milestones:

FDA Pathway

Conformal Medical will need to complete the CONFORM pivotal trial and submit the results to FDA. The most likely regulatory pathway is:

1. PMA (Pre-Market Approval) — As a Class III implantable cardiovascular device intended for permanent implantation, LAAO devices typically require PMA approval, the most stringent FDA device regulatory pathway.
2. Clinical data requirements — The 1,600-patient CONFORM trial will need to demonstrate safety and effectiveness compared to the standard of care (oral anticoagulation or WATCHMAN/Amulet).
3. Advisory panel — Given the competitive landscape and the novel foam-based technology, FDA may convene an advisory panel meeting before making a decision.

The regulatory timeline from trial completion to FDA decision could span 12–24 months, meaning the earliest potential US market entry for the CLAAS AcuForm is likely 2027–2028.

EU MDR Pathway

In the EU, LAAO devices are classified as Class III under the MDR (EU 2017/745). Conformal Medical would need:

• Conformity assessment by a notified body
• Clinical evidence supporting safety and performance under Annex XIV
• CE marking under the MDR

The EU MDR's stricter clinical evidence requirements compared to the previous MDD directive may require additional clinical data beyond what is collected in the CONFORM trial.

Implications for the MedTech Industry

For Structural Heart Companies

1. The LAAO market is entering a new competitive phase. Gore's entry, combined with J&J's Laminar acquisition, means the days of a comfortable Boston Scientific–Abbott duopoly are numbered. Companies in adjacent spaces (electrophysiology, interventional cardiology) should evaluate whether LAAO fits into their portfolio strategies.

2. Technology convergence is coming. Boston Scientific is already positioning LAAO as "foundation to a comprehensive AF management strategy." The future may see combined devices that address both the LAA closure and the arrhythmia itself (through pulsed-field ablation), creating dual-therapy platforms.

3. Clinical evidence is the battleground. With multiple devices competing for the same indication, the quality and breadth of clinical data will be the primary differentiator. Companies investing in large, well-designed pivotal trials will have a significant competitive advantage.

For Hospitals and Interventionalists

1. More device options are coming. The competitive expansion should provide interventionalists with a broader range of LAAO devices suited to different anatomies and clinical scenarios.

2. Conformable technology could simplify procedures. If Conformal's one-size-fits-most approach proves effective, it could reduce procedure complexity, inventory costs, and the need for pre-procedural imaging for size selection.

3. Expanded indications could transform the market. If Boston Scientific succeeds in expanding the WATCHMAN indication to all AFib patients (not just those who cannot tolerate anticoagulation), it would dramatically increase the addressable market — benefiting all LAAO device manufacturers.

Key Takeaways

• W.L. Gore completed its acquisition of Conformal Medical on February 19, 2026, adding the investigational CLAAS AcuForm foam-based LAAO system to its cardiovascular portfolio
• The deal is a rare strategic acquisition by privately held Gore, signaling strong conviction in the $1.2B+ LAAO device market
• Conformal's CLAAS AcuForm uses a foam-based, one-size-fits-most approach that differs fundamentally from nitinol frame devices from Boston Scientific (WATCHMAN) and Abbott (Amulet)
• The device is in the CONFORM pivotal trial (1,600 patients, ~30% enrolled at acquisition); regulatory approval is likely 2027–2028 at earliest
• Gore's materials science expertise and existing endovascular sales infrastructure provide natural synergies for LAAO commercialization
• The LAAO market is transitioning from a near-duopoly to a multi-player competitive landscape, with J&J (Laminar) and Gore (Conformal) joining incumbents